Titre : Gouvernement fédéral

Gouvernement fédéral : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multicenter Studies as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Gouvernement fédéral : Questions médicales les plus fréquentes", "headline": "Gouvernement fédéral : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Gouvernement fédéral : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-11", "dateModified": "2025-03-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Gouvernement fédéral" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Agences gouvernementales", "url": "https://questionsmedicales.fr/mesh/D006077", "about": { "@type": "MedicalCondition", "name": "Agences gouvernementales", "code": { "@type": "MedicalCode", "code": "D006077", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.540.400" } } }, "about": { "@type": "MedicalCondition", "name": "Gouvernement fédéral", "alternateName": "Federal Government", "code": { "@type": "MedicalCode", "code": "D035082", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sara Allin", "url": "https://questionsmedicales.fr/author/Sara%20Allin", "affiliation": { "@type": "Organization", "name": "North American Observatory on Health Systems and Policies, Toronto, ON Canada." } }, { "@type": "Person", "name": "Gul Mehar Javaid Bukhari", "url": "https://questionsmedicales.fr/author/Gul%20Mehar%20Javaid%20Bukhari", "affiliation": { "@type": "Organization", "name": "Federal Medical & Dental College, Islamabad, Pakistan." } }, { "@type": "Person", "name": "R U Khabriev", "url": "https://questionsmedicales.fr/author/R%20U%20Khabriev", "affiliation": { "@type": "Organization", "name": "N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia." } }, { "@type": "Person", "name": "Lizhen Cui", "url": "https://questionsmedicales.fr/author/Lizhen%20Cui", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Noël E Smith", "url": "https://questionsmedicales.fr/author/No%C3%ABl%20E%20Smith", "affiliation": { "@type": "Organization", "name": "American Academy of PAs, 2318 Mill Road, Suite 1300, Alexandria, VA 22314." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Evaluation of the physical and emotional effects of the COVID-19 pandemic on patients with fibromyalgia and chronic low back pain: A multicenter cross-sectional controlled study.", "datePublished": "2022-11-22", "url": "https://questionsmedicales.fr/article/36589358", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5606/tftrd.2022.10053" } }, { "@type": "ScholarlyArticle", "name": "Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study.", "datePublished": "2022-10-31", "url": "https://questionsmedicales.fr/article/36260658", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ajh.26769" } }, { "@type": "ScholarlyArticle", "name": "Prevalence and Risk Factor Analysis of Post-Intensive Care Syndrome in Patients with COVID-19 Requiring Mechanical Ventilation: A Multicenter Prospective Observational Study.", "datePublished": "2022-09-28", "url": "https://questionsmedicales.fr/article/36233627", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/jcm11195758" } }, { "@type": "ScholarlyArticle", "name": "Predictors of transfer from a remote trauma facility to an urban level I trauma center for blunt splenic injuries: a retrospective observational multicenter study.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36085048", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13037-022-00339-4" } }, { "@type": "ScholarlyArticle", "name": "Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36140344", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/biomedicines10092243" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Organismes", "item": "https://questionsmedicales.fr/mesh/D009938" }, { "@type": "ListItem", "position": 4, "name": "Agences gouvernementales", "item": "https://questionsmedicales.fr/mesh/D006077" }, { "@type": "ListItem", "position": 5, "name": "Gouvernement fédéral", "item": "https://questionsmedicales.fr/mesh/D035082" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Gouvernement fédéral - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Gouvernement fédéral", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Gouvernement fédéral", "description": "Comment le gouvernement fédéral évalue-t-il les épidémies ?\nQuelles sont les méthodes de surveillance des maladies ?\nQuel rôle joue le gouvernement dans le diagnostic des maladies ?\nComment le gouvernement fédéral soutient-il le diagnostic précoce ?\nQuelles sont les normes de diagnostic établies par le gouvernement ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=995#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Gouvernement fédéral", "description": "Comment le gouvernement informe-t-il sur les symptômes des maladies ?\nQuels symptômes sont souvent associés aux épidémies ?\nComment le gouvernement traite-t-il les symptômes des maladies chroniques ?\nQuelles ressources le gouvernement offre pour les symptômes mentaux ?\nComment le gouvernement évalue-t-il les symptômes des nouvelles maladies ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=995#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Gouvernement fédéral", "description": "Quelles campagnes de prévention le gouvernement mène-t-il ?\nComment le gouvernement soutient-il la prévention des maladies chroniques ?\nQuelles sont les recommandations gouvernementales pour la prévention ?\nComment le gouvernement évalue-t-il l'efficacité des programmes de prévention ?\nQuelles ressources le gouvernement offre pour la prévention des maladies ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=995#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Gouvernement fédéral", "description": "Quel est le rôle du gouvernement dans le financement des traitements ?\nComment le gouvernement régule-t-il les traitements médicaux ?\nQuelles sont les initiatives gouvernementales pour les traitements innovants ?\nComment le gouvernement assure-t-il l'accès aux traitements ?\nQuelles sont les politiques de traitement des maladies infectieuses ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=995#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Gouvernement fédéral", "description": "Comment le gouvernement gère-t-il les complications des maladies ?\nQuelles sont les complications courantes des maladies infectieuses ?\nComment le gouvernement informe-t-il sur les complications possibles ?\nQuelles sont les politiques pour gérer les complications des maladies chroniques ?\nComment le gouvernement évalue-t-il les complications des traitements ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=995#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Gouvernement fédéral", "description": "Quels facteurs de risque le gouvernement identifie-t-il ?\nComment le gouvernement aborde-t-il les facteurs de risque ?\nQuelles données le gouvernement utilise pour évaluer les facteurs de risque ?\nComment le gouvernement sensibilise-t-il aux facteurs de risque ?\nQuelles initiatives le gouvernement prend-il pour réduire les facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=995#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le gouvernement fédéral évalue-t-il les épidémies ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Il utilise des données épidémiologiques et des rapports de santé publique pour évaluer les épidémies." } }, { "@type": "Question", "name": "Quelles sont les méthodes de surveillance des maladies ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent les enquêtes, les systèmes de notification et les analyses de données." } }, { "@type": "Question", "name": "Quel rôle joue le gouvernement dans le diagnostic des maladies ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Il établit des protocoles de diagnostic et finance des recherches pour améliorer les méthodes." } }, { "@type": "Question", "name": "Comment le gouvernement fédéral soutient-il le diagnostic précoce ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Il finance des programmes de dépistage et sensibilise le public aux signes précoces." } }, { "@type": "Question", "name": "Quelles sont les normes de diagnostic établies par le gouvernement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement établit des lignes directrices basées sur des preuves pour le diagnostic." } }, { "@type": "Question", "name": "Comment le gouvernement informe-t-il sur les symptômes des maladies ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Il publie des brochures, des sites web et des campagnes de sensibilisation sur les symptômes." } }, { "@type": "Question", "name": "Quels symptômes sont souvent associés aux épidémies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, mais incluent souvent fièvre, toux, et fatigue selon la maladie." } }, { "@type": "Question", "name": "Comment le gouvernement traite-t-il les symptômes des maladies chroniques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il finance des programmes de gestion des maladies chroniques et des traitements symptomatiques." } }, { "@type": "Question", "name": "Quelles ressources le gouvernement offre pour les symptômes mentaux ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Il propose des lignes d'assistance, des programmes de santé mentale et des ressources en ligne." } }, { "@type": "Question", "name": "Comment le gouvernement évalue-t-il les symptômes des nouvelles maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Il collabore avec des experts pour identifier et évaluer les symptômes émergents." } }, { "@type": "Question", "name": "Quelles campagnes de prévention le gouvernement mène-t-il ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il organise des campagnes de vaccination, de dépistage et de sensibilisation à la santé." } }, { "@type": "Question", "name": "Comment le gouvernement soutient-il la prévention des maladies chroniques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il finance des programmes de promotion de la santé et d'éducation sur les modes de vie sains." } }, { "@type": "Question", "name": "Quelles sont les recommandations gouvernementales pour la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement publie des lignes directrices sur l'alimentation, l'exercice et le dépistage." } }, { "@type": "Question", "name": "Comment le gouvernement évalue-t-il l'efficacité des programmes de prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Il utilise des études d'impact et des analyses de données pour évaluer les programmes." } }, { "@type": "Question", "name": "Quelles ressources le gouvernement offre pour la prévention des maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il propose des ressources en ligne, des brochures et des ateliers communautaires." } }, { "@type": "Question", "name": "Quel est le rôle du gouvernement dans le financement des traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il finance la recherche et l'accès aux traitements par le biais de subventions et de programmes." } }, { "@type": "Question", "name": "Comment le gouvernement régule-t-il les traitements médicaux ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il établit des agences pour approuver et surveiller les traitements avant leur mise sur le marché." } }, { "@type": "Question", "name": "Quelles sont les initiatives gouvernementales pour les traitements innovants ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement soutient des programmes de recherche et des essais cliniques pour les innovations." } }, { "@type": "Question", "name": "Comment le gouvernement assure-t-il l'accès aux traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il met en place des programmes d'assurance santé et des politiques d'accès aux soins." } }, { "@type": "Question", "name": "Quelles sont les politiques de traitement des maladies infectieuses ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement élabore des protocoles de traitement basés sur des recommandations scientifiques." } }, { "@type": "Question", "name": "Comment le gouvernement gère-t-il les complications des maladies ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Il met en place des protocoles de traitement et des programmes de suivi pour les complications." } }, { "@type": "Question", "name": "Quelles sont les complications courantes des maladies infectieuses ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des infections secondaires, des séquelles et des hospitalisations." } }, { "@type": "Question", "name": "Comment le gouvernement informe-t-il sur les complications possibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Il publie des informations sur les risques et les complications associés aux maladies." } }, { "@type": "Question", "name": "Quelles sont les politiques pour gérer les complications des maladies chroniques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement finance des programmes de gestion des complications et de réhabilitation." } }, { "@type": "Question", "name": "Comment le gouvernement évalue-t-il les complications des traitements ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Il surveille les effets secondaires et les complications par le biais de systèmes de rapport." } }, { "@type": "Question", "name": "Quels facteurs de risque le gouvernement identifie-t-il ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Il identifie des facteurs comme le tabagisme, l'obésité et le manque d'exercice dans ses études." } }, { "@type": "Question", "name": "Comment le gouvernement aborde-t-il les facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Il met en place des politiques de santé publique pour réduire les facteurs de risque identifiés." } }, { "@type": "Question", "name": "Quelles données le gouvernement utilise pour évaluer les facteurs de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Il utilise des enquêtes de santé, des études épidémiologiques et des données démographiques." } }, { "@type": "Question", "name": "Comment le gouvernement sensibilise-t-il aux facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Il organise des campagnes d'éducation et de sensibilisation sur les comportements à risque." } }, { "@type": "Question", "name": "Quelles initiatives le gouvernement prend-il pour réduire les facteurs de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Il finance des programmes de prévention et des interventions communautaires ciblées." } } ] } ] }

Sources (10000 au total)

Evaluation of the physical and emotional effects of the COVID-19 pandemic on patients with fibromyalgia and chronic low back pain: A multicenter cross-sectional controlled study.

This study aimed to investigate the physical and emotional effects of the coronavirus disease 2019 pandemic in patients with fibromyalgia syndrome (FMS) and chronic low back pain (CLBP) patients.... The cross-sectional controlled study was performed with 1,360 participants (332 males, 1,028 females; mean age: 42.3±12.5 years; range, 18 to 65 years) between September 2020 and February 2021. The pa... Patients with FMS had worsened general health status and pain levels during the pandemic compared to the other groups (p<0.01). The FMS group showed significantly higher PSS scores than those in other... The general health status, pain, and stress levels of the patients with FMS and CLBP tended to worsen during the pandemic. This high-stress level appeared to affect disease activity in patients with F...

Prevalence and Risk Factor Analysis of Post-Intensive Care Syndrome in Patients with COVID-19 Requiring Mechanical Ventilation: A Multicenter Prospective Observational Study.

Post-intensive care syndrome (PICS) is an emerging problem in critically ill patients and the prevalence and risk factors are unclear in patients with severe coronavirus disease 2019 (COVID-19). This ... Questionnaires were administered twice in surviving patients with COVID-19 who had required mechanical ventilation, concerning Barthel Index, Short-Memory Questionnaire, and Hospital Anxiety and Depre... The first and second PICS surveys were obtained at 5.5 and 13.5 months (mean) after ICU discharge, with 251 and 209 patients completing the questionnaires and with a prevalence of PICS of 58.6% and 60... Approximately 60% of the ventilated patients with COVID-19 experienced persistent PICS, especially delirium, and required longer mechanical ventilation....

Predictors of transfer from a remote trauma facility to an urban level I trauma center for blunt splenic injuries: a retrospective observational multicenter study.

The decision-making for admission versus emergent transfer of patients with blunt splenic injuries presenting to remote trauma centers with limited resources remains a challenge. Although splenectomy ... A retrospective observational study was performed to examine the management of splenic injuries at a mountainous and remote Level III trauma center. Trauma patients ≥ 18 years who had a blunt splenic ... Of the 73 patients included with a blunt splenic injury, 48% were admitted and 52% were transferred to a Level I facility. Most patients were male (n = 58), were a median age of 26 (21-42) years old, ... Our data suggest that most patients transferred from a remote facility had a splenic injury grade ≥ 3, with concomitant injuries but were hemodynamically stable and were successfully managed non-opera...

RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design.

Tirofiban is a glycoprotein IIb/IIIa receptor inhibitor that has been shown to be effective in the treatment of acute coronary syndromes. However, it remains unknown whether it improves outcomes in pa... This trial investigates the efficacy and safety of tirofiban compared with aspirin for acute ischemic stroke within 24 h after symptom onset.... The Efficacy and Safety of Tirofiban Compared with Aspirin in the Treatment of Acute Ischemic Stroke (RESCUE BT 2) Trial is an investigator-initiated, prospective, randomized, double-blind, double-dum... The primary endpoint is the proportion of patients with excellent functional outcomes defined as a modified Rankin scale score of 0 to 1 at 90 days after randomization. Lead safety endpoints include m... ChiCTR2000029502 (www.chictr.org.cn)....

Endometrial Cancer Detection Using a Cervical DNA Methylation Assay (MPap) in Women with Abnormal Uterine Bleeding: A Multicenter Hospital-Based Validation Study.

We describe a DNA methylation assay, named MPap test, using cervical scraping as an alternative technique for endometrial cancer detection.... A multicenter hospital-based, two-stage validation study was conducted to validate the cancer detection performance of the MPap test. The MPap value was determined from the DNA methylation status of t... In stage 1, the sensitivity, specificity, and positive and negative predictive values of the MPap test for detecting endometrial cancer were 92.9%, 71.5%, 39.8%, and 98.0%, respectively. These values ... MPap may provide a feasible alternative for endometrial cancer detection and can be considered as a triage test to reduce unnecessary invasive procedures....

Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.

Pediatric pneumococcal conjugate vaccines (PCVs) introduction has directly and indirectly reduced pneumococcal pneumonia and invasive disease caused by PCV-covered serotypes among children and adults ... We assessed serotypes isolated from adult pneumococcal pneumonia patients (in- and outpatients) in two multicenter observational studies in Japan: 2011-2014 and 2016-2020. The latter study period was ... A total of 650 patients were enrolled: 224, 322, and 104 in 2011-2014, 2016-2017, and 2018-2020, respectively. The median age was 73 years; 59.7% (388/650) were male; 86.9% (565/650) had comorbidities... The proportion of adult pneumococcal pneumonia caused by PCV13 serotypes in Japan declined after pediatric PCVs introduction into NIP, possibly due to indirect effects of pediatric PCVs. However, use ...

Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.

Targeting Kirsten Rat Sarcoma (KRAS) has been deemed impossible for long time, but new drugs have recently demonstrated promising results. Evidence on the outcome of KRAS-mutant advanced-NSCLC treated... The present multicenter retrospective study, conducted by 5 Italian Centers from January 2018 to February 2020, involved 297 advanced KRAS mutant NSCLC. Complete clinico-pathological data were evaluat... Out of 297 patients, 130 carried KRAS_G12C mutation, while 167 presented with mutations other than G12C. Within KRAS_non-G12C group, 73%, 16.8% and 8.9% harboured G12X, codon 13 and Q61H alterations, ... Here, we report on real-life data from a large retrospective cohort of advanced NSCLC harbouring KRAS alterations, with particular attention to G12C mutation. Our study offers useful clues on survival...

Clinical and radiographic outcomes following transcrestal maxillary sinus floor elevation with injectable xenogenous bone substitute in gel form: a prospective multicenter study.

To investigate clinical and radiographic outcomes of transcrestal maxillary sinus floor elevation performed with an injectable xenograft in gel form, analyzing general, local and surgical variables po... Patients with residual crestal height < 5 mm underwent transcrestal sinus floor elevation with xenograft in gel form to allow the placement of a single implant. Simultaneous implant placement was perf... 71 patients underwent transcrestal sinus floor elevation and 54 implants were simultaneously placed. Delayed implant placement (at T1) was possible in 5 cases out of 17 (29.4%), whereas in 12 patients... Transcrestal sinus floor elevation performed with injectable xenograft gel resulted in 100% implant survival rate. However, immediate implant insertion seems a crucial factor to preserve vertical bone...